Author

G. I. Shapiro

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. D. D'Andrea· 2 shared B. Kochupurakkal· 2 shared C. Pantelidou· 2 shared A. Farkkila· 1 shared A. G. Waks· 1 shared A. Kothari· 1 shared A. Li· 1 shared A. Raimondi· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. D. D'Andrea

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes

Y. Huang, R. T. Durall, N. M. Luong, H. J. Hertzler, J. Huang, P. C. Gokhale, B. A. Leeper, N. S. Persky, D. E. Root, P. V. Anekal, P. D. Montero Llopis, C. N. David, J. L. Kutok, A. Raimondi, K. Saluja, , C. A. French

This study identifies EZH2 as a dependency in NUT carcinoma, showing that combining EZH2 and BET inhibitors synergistically blocks tumor growth and prolongs survival.

bioRxiv · Aug 15, 2023Cancer Biology

STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer

C. Pantelidou, H. Jadhav, A. Kothari, R. Liu, J. L. Guerriero, G. I. Shapiro

bioRxiv · Jan 26, 2021Cancer Biology

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors

J. Zhou, C. Gelot, C. Pantelidou, A. Li, H. Yucel, R. E. Davis, A. Farkkila, B. Kochupurakkal, A. Syed, G. I. Shapiro, J. A. Tainer, B. S. Blagg, R. Ceccaldi, A. D. D'Andrea

The paper identifies Novobiocin as a POLθ inhibitor that selectively kills HR-deficient tumors, including those resistant to PARP inhibitors.

bioRxiv · May 23, 2020Cancer Biology

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd, L. Marini, M. E. Hughes, S. S. Freeman, S. P. Ivy, J. Geradts, S. Isakoff, , N. Wagle

This study identifies genomic reversion and increased DNA end resection as mechanisms of resistance to PARP inhibitors and platinum in BRCA1/2-mutant metastatic breast cancer, with RAD51 foci as a potential biomarker.

bioRxiv · Nov 10, 2019Cancer Biology